The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers

ConclusionsParoxetine-induced increases in exposure to the active deutetrabenazine metabolites were less than those previously reported for tetrabenazine, a finding expected to reduce the burden of drug interaction. In addition, single doses of 22.5  mg deutetrabenazine, when given alone or in the presence of steady-state paroxetine (20 mg daily), were safe.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research